Search

Displaying results 4651 - 4660 of 8974 in total
  1. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  2. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    TC-6987

    go.drugbank.com/drugs/DB14854
    Investigational

    TC-6987 is under investigation in clinical trial NCT01296087 (TC-6987 for the Treatment of Mild to Moderate Asthma).

  4. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  5. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  6. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  7. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  8. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism. … ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform.

  9. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.

  10. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.